Ann: Investor Presentation, page-7

First 7 Last

Share
Profile

Follow
Eqz

3,459 Posts.

1134

21/06/21

13:40

Post #: 53966501
Share

Originally posted by candidcamera: ↑

Unfortunately, my unpopular view that I've expressed before still stands. This company doesn't have the revenue to warrant a higher share price and frankly, with around $1 million in revenue per year, and 120 million shares on offer, I'm surprised it's as high as it is.

What makes it really disappointing and bewildering for me is that the company has so much going for it:
– Unique and life-changing products that deliver great patient outcomes.
– A company that's been around for over 20 years, selling its products for over 15, 40,000+ successful operations (so lots of stats to back it up).
– Sound management.
– Good and relevant partnerships.
– Increasing diversity with a pipeline of new products and whole areas into which it can grow.
– Relevant permissions in place to sell into the biggest markets in the world (China, USA and Europe).
– Distribution deals to take advantage of those permissions.
– Very positive media and medical commentary.
– A tiny foothold in a multi-billion dollar industry (hence a very long runway for growth)

On paper, you have to think (scream!): What's not to like?

I don't think it's a failing of the management or the sales teams. It's just that hospitals aren't buying it in anywhere near the number required for a share price movement. They're not buying it because the doctors aren't recommending it (stuck on their traditional, tried-and-true products?). Sure, the Q-on-Q percentage increases look good. But when you're starting from such a very low base, that's not so impressive. It's the revenue that counts and until that goes up – substantially, like around 10x what it is now – I can't see how the share price will go up.

I'm only holding because I don't want to realise the loss, so might as well hang on and hope. Now, I'm hoping that a big medtech buys OSX, because I think it's unrealistic to expect the kind of organic growth that would be needed to get the share price over $1.

Expand

Can you give me an examples of micro cap Biotech where revenues justify its market cap?

$50M is well priced in comparison to the industry and its peers.

I'm starting to lose my patience a tad, admittedly it is holding up pretty well given the tax month. If it was not for the cash position I would be out.

OSX Price at posting: 43.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BM8

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

PME

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

JBY

James Bay latest lithium player to pivot to other metals amidst lithium slump

There are more pages in this discussion • 4 more messages in this thread...

First 7 Last

Add OSX (ASX) to my watchlist

(20min delay)
Last 3.8¢		Change -0.001(2.56%)		Mkt cap ! $4.390M

Open	High	Low	Value	Volume
3.8¢	3.9¢	3.6¢	$32.18K	881.2K

Buyers (Bids)

No.	Vol.	Price($)
2	40237	3.7¢

Sellers (Offers)

Price($)	Vol.	No.
3.8¢	99999	1

View Market Depth

No.	Vol.	Price($)
2	40237	0.037
4	103277	0.036
5	269085	0.035
2	108235	0.034
1	18181	0.033

Price($)	Vol.	No.
0.039	77294	2
0.040	300000	2
0.041	244192	3
0.042	297766	2
0.043	309670	2

Last trade - 16.10pm 16/10/2024 (20 minute delay)

OSX (ASX) Chart

Ann: Investor Presentation, page-7

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

James Bay latest lithium player to pivot to other metals amidst lithium slump

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-7

Top Stories

Battery Age Minerals gets set to capitalise on critical mineral demand

ASX Market Update: Index pulls back from record highs | October 16, 2024

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

James Bay latest lithium player to pivot to other metals amidst lithium slump

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News